New drugs for BNCT: An experimental approach

Lothar Weissfloch; Michael Bremer; Peter Lemmen; Thomas Probst; Matthias Wagner; Michael Peller; Thomas Auberger; Reingard Senekowitsch-Schmidtke; Karlheinz Tempel; Michael Molls

doi:10.1007/bf03038909

New drugs for BNCT: An experimental approach

Lothar Weissfloch
, Michael Bremer
, Peter Lemmen
, Thomas Probst
, Matthias Wagner
, Michael Peller
, Thomas Auberger
, Reingard Senekowitsch-Schmidtke
, Karlheinz Tempel
, Michael Molls

Technical University of Munich
Brookhaven National Laboratory

Research output: Contribution to journal › Article › peer-review

Abstract

New kinds of boron-containing drugs were developed and tested in several murine tumor models. The boron-containing ether lipid B-Et-11-OMe was injected in mammary carcinoma (AT17) and osteosarcoma (OTS-64) bearing mice. Furthermore boron-substituted ferrocenium derivatives were tested. Two were excessively toxic; the third could be investigated. Boron accumulation and time-dependent biodistribution were determined using alpha-particle sensitive films and inductively coupled plasma-atomic emission pectrometry (ICP-AES) and -mass spectrometry (ICP-MS) of tumors, organs and tissues. Additionally, a new method of boron detection by NMR is in preparation.

Original language	English
Pages (from-to)	118-120
Number of pages	3
Journal	Strahlentherapie und Onkologie
Volume	175
Issue number	SUPPL. 2
DOIs	https://doi.org/10.1007/bf03038909
State	Published - Jun 1999

Keywords

BNCT
Ether lipid
Ferrocenium
Mouse
Tumor model

Access to Document

10.1007/bf03038909

Cite this

@article{8a2aba4a4151413787139827f4366584,

title = "New drugs for BNCT: An experimental approach",

abstract = "New kinds of boron-containing drugs were developed and tested in several murine tumor models. The boron-containing ether lipid B-Et-11-OMe was injected in mammary carcinoma (AT17) and osteosarcoma (OTS-64) bearing mice. Furthermore boron-substituted ferrocenium derivatives were tested. Two were excessively toxic; the third could be investigated. Boron accumulation and time-dependent biodistribution were determined using alpha-particle sensitive films and inductively coupled plasma-atomic emission pectrometry (ICP-AES) and -mass spectrometry (ICP-MS) of tumors, organs and tissues. Additionally, a new method of boron detection by NMR is in preparation.",

keywords = "BNCT, Ether lipid, Ferrocenium, Mouse, Tumor model",

author = "Lothar Weissfloch and Michael Bremer and Peter Lemmen and Thomas Probst and Matthias Wagner and Michael Peller and Thomas Auberger and Reingard Senekowitsch-Schmidtke and Karlheinz Tempel and Michael Molls",

year = "1999",

month = jun,

doi = "10.1007/bf03038909",

language = "English",

volume = "175",

pages = "118--120",

journal = "Strahlentherapie und Onkologie",

issn = "0179-7158",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "SUPPL. 2",

}

TY - JOUR

T1 - New drugs for BNCT

T2 - An experimental approach

AU - Weissfloch, Lothar

AU - Bremer, Michael

AU - Lemmen, Peter

AU - Probst, Thomas

AU - Wagner, Matthias

AU - Peller, Michael

AU - Auberger, Thomas

AU - Senekowitsch-Schmidtke, Reingard

AU - Tempel, Karlheinz

AU - Molls, Michael

PY - 1999/6

Y1 - 1999/6

N2 - New kinds of boron-containing drugs were developed and tested in several murine tumor models. The boron-containing ether lipid B-Et-11-OMe was injected in mammary carcinoma (AT17) and osteosarcoma (OTS-64) bearing mice. Furthermore boron-substituted ferrocenium derivatives were tested. Two were excessively toxic; the third could be investigated. Boron accumulation and time-dependent biodistribution were determined using alpha-particle sensitive films and inductively coupled plasma-atomic emission pectrometry (ICP-AES) and -mass spectrometry (ICP-MS) of tumors, organs and tissues. Additionally, a new method of boron detection by NMR is in preparation.

AB - New kinds of boron-containing drugs were developed and tested in several murine tumor models. The boron-containing ether lipid B-Et-11-OMe was injected in mammary carcinoma (AT17) and osteosarcoma (OTS-64) bearing mice. Furthermore boron-substituted ferrocenium derivatives were tested. Two were excessively toxic; the third could be investigated. Boron accumulation and time-dependent biodistribution were determined using alpha-particle sensitive films and inductively coupled plasma-atomic emission pectrometry (ICP-AES) and -mass spectrometry (ICP-MS) of tumors, organs and tissues. Additionally, a new method of boron detection by NMR is in preparation.

KW - BNCT

KW - Ether lipid

KW - Ferrocenium

KW - Mouse

KW - Tumor model

UR - https://www.scopus.com/pages/publications/0032742710

U2 - 10.1007/bf03038909

DO - 10.1007/bf03038909

M3 - Article

C2 - 10394418

AN - SCOPUS:0032742710

SN - 0179-7158

VL - 175

SP - 118

EP - 120

JO - Strahlentherapie und Onkologie

JF - Strahlentherapie und Onkologie

IS - SUPPL. 2

ER -

New drugs for BNCT: An experimental approach

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this